The Role of Inflammatory Proteins in Anti-Glucocorticoid Therapy for Treatment-Resistant Depression.
Rebecca StrawbridgeAlzbeta JamiesonJohn HodsollIan Nicol FerrierRichard Hamish McAllister-WilliamsTimothy R PowellAllan H YoungAnthony J CleareStuart WatsonPublished in: Journal of clinical medicine (2021)
Metyrapone is hypothesised to have a therapeutic effect in depression on the basis of inhibiting the synthesis of cortisol. In this study, metyrapone did not reduce cortisol, possibly due to glucocorticoid system overcompensation). The mediation effect of IL-6 may support this and perhaps help to indicate why the treatment was not effective.